-
CMS reports home health claims problem; Random unannounced survey topics identified.
-
Preventing, diagnosing, and treating infections in home care patients require careful surveillance and a high level of awareness of infection control on the part of a home health nurse. You may think your agency is doing a good job of preventing infections, but how can you tell?
-
Paying attention to a myriad of small signs in both the caregivers and the patients behavior can alert the home health nurse to a need for intervention, says Nancy Stallings, MAM, program manager for caregiver support for Salt Lake County Aging Services in Salt Lake City.
-
Editors note: This is a periodic column that will address specific questions related to Health Insurance Portability and Accountability HIPAA) implementation.
-
This is the second of a two-part LegalEase column that addresses home health agency concerns related to changes in state Medicaid programs. This column looks at nursing implications and violation of ethical principles. Last months column presented background on the Medicaid reimbursement crisis and described Medicaid program changes that can affect home health agencies with charges of fraud and abuse, risk of legal liability, and loss of professional licensure.
-
-
In the constantly shifting landscape of drug resistance, antibiotic options, and pharmacoeconomic considerations, urinary tract infection continues to be one of the most frequently diagnosed conditions in patients presenting to the emergency department.
-
Recently, the Centers for Medicare and Medicaid Services proposed several changes to EMTALA that attempt to clarify hospital and physician duties. Undoubtedly, this new legislation will have an impact upon the care of emergency patients and the emergency physicians caring for them.
-
-
The trial concluded that platinum-based adjuvant chemotherapy improved overall survival and recurrence-free survival at 5 years in this combined group of patients with early stage ovarian cancer defined by the inclusion criteria of the ICON1 and ACTION trials.
